The therapeutic effect of B-type natriuretic peptides in acute decompensated heart failure.
B-type natriuretic peptide
clinical effectiveness
heart failure
pharmacotherapy
Journal
Clinical and experimental pharmacology & physiology
ISSN: 1440-1681
Titre abrégé: Clin Exp Pharmacol Physiol
Pays: Australia
ID NLM: 0425076
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
06
11
2019
revised:
03
02
2020
accepted:
19
02
2020
pubmed:
23
2
2020
medline:
12
10
2021
entrez:
22
2
2020
Statut:
ppublish
Résumé
B-type natriuretic peptide (BNP) exhibits roles in natriuresis and diuresis, making it an ideal drug that may aid in diuresing a fluid-overloaded patient with poor or worsening renal function. Several randomized clinical trials have tested the hypothesis that infusions of pharmacological doses of BNP to acute heart failure (HF) patients may enhance decongestion and preserve renal function in this clinical setting. Unfortunately, none of these have demonstrated beneficial outcomes. The current challenge for BNP research in acute HF lies in addressing a failure of concept and a reluctance to abandon an ineffective research model. Future success will necessitate a detailed understanding of the mechanism of action of BNP, as well as better integration of basic and clinical science.
Identifiants
pubmed: 32083749
doi: 10.1111/1440-1681.13290
doi:
Substances chimiques
Natriuretic Peptide, Brain
114471-18-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1120-1133Informations de copyright
© 2020 John Wiley & Sons Australia, Ltd.
Références
Wong PCY, Guo J, Zhang A. The renal and cardiovascular effects of natriuretic peptides. Adv Physiol Educ. 2017;41:179-185.
Clerico A, Giannoni A, Vittorini S, Passino C. Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones. Am J Physiol Heart Circ Physiol. 2011;301:H12-20.
Shimizu H, Masuta K, Asada H, Sugita K, Sairenji T. Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin Chim Acta. 2003;334:233-239.
de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;362:316-322.
Iwanaga Y, Nishi I, Furuich S, et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure. J Am Coll Cardiol. 2006;47:742-748.
Brunner-La Rocca HP, Kaye DM, Woods RL, Hastings J, Esler MD. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol. 2001;37:1221-1227.
George I, Xydas S, Klotz S, et al. Long-term effects of B-type natriuretic peptide infusion after acute myocardial infarction in a rat model. J Cardiovasc Pharmacol. 2010;55:14-20.
Tamura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci. 2000;97:4239-4244.
Horio T, Nishikimi T, Yoshihara F, Matsuo H, Takishita S, Kangawa K. Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. Hypertension. 2000;35:19-24.
Redondo J, Bishop JE, Wilkins MR. Effect of atrial natriuretic peptide and cyclic GMP phosphodiesterase inhibition on collagen synthesis by adult cardiac fibroblasts. Br J Pharmacol. 1998;124:1455-1462.
Hayashi M, Tsutamoto T, Wada A, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol. 2001;37:1820-1826.
Arora RR, Venkatesh PK, Molnar J. Short and long-term mortality with nesiritide. Am Heart J. 2006;152:1084-1090.
O’Connor CM, Starling RCH, Hernandez AF et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32-43.
Chen HH, Schirger JA, Chau WL, et al. Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure. Circulation. 1999;100:2443-2448.
Margulies KB, Heublein DM, Perrella MA, Burnett JC. ANF-mediated renal cGMP generation in congestive heart failure. Am J Physiol Physiol. 1991;260:F562-F568.
Meyer M, Zhang Q, Khurana K, Scholz PM, Weiss HR. Negative functional effects of natriuretic peptides are attenuated in hypertrophic cardiac myocytes by reduced particulate guanylyl cyclase activity. J Cardiovasc Pharmacol. 2007;49:100-105.
Burnett JC Jr. Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens Suppl. 1999;17:S37-S43.
Chun TH, Itoh H, Ogawa Y, et al. Shear stress augments expression of C-type natriuretic peptide and adrenomedullin. Hypertension. 1997;29:1296-1302.
Suga S, Itoh H, Komatsu Y, et al. Cytokine-induced C-type natriuretic peptide (CNP) secretion from vascular endothelial cells-evidence for CNP as a novel autocrine/paracrine regulator from endothelial cells. Endocrinology. 1993;133:3038-3041.
Del Ry S, Cabiati M, Vozzi F, et al. Expression of C-type natriuretic peptide and its receptor NPR-B in cardiomyocytes. Peptides. 2011;32:1713-1718.
Wu C, Wu F, Pan J, Morser J, Wu Q. Furin-mediated processing of pro-C-type natriuretic peptide. J Biol Chem. 2003;278:25847-25852.
Brown J, Chen Q, Hong G. An autocrine system for C-type natriuretic peptide within rat carotid neointima during arterial repair. Am J Physiol. 1997;272:H2919-H2931.
Del Ry S, Giannessi D, Maltinti M, et al. Increased levels of C-type natriuretic peptide in patients with idiopathic left ventricular dysfunction. Peptides. 2007;28:1068-1073.
Sonnenberg JL, Sakane Y, Jeng AY, et al. Identification of protease 3.4.24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidney. Peptides. 1988;9:173-180.
Vanderheyden M, Bartunek J, Goethals M, et al. Dipeptidyl-peptidase IV and B-type natriuretic peptide. from bench to bedside. Clin Chem Lab Med. 2009;47:248-252.
Elgendy IY, Mahmoud AN, Barakat AF, et al. Cardiovascular safety of dipeptidyl-peptidase iv inhibitors: a meta-analysis of placebo-controlled randomized trials. Am J Cardiovasc Drugs. 2017;17:143-155.
Li L, Li S, Deng K, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ. 2016;352:i610.
Kalra PR, Clague JR, Bolger AP, et al. Myocardial production of c-type natriuretic peptide in chronic heart failure. Circulation. 2003;107:571-573.
Del Ry S, Passino C, Maltinti M, Emdin M, Giannessi D. C-type natriuretic peptide plasma levels increase in patients with chronic heart failure as a function of clinical severity. Eur J Heart Fail. 2005;7:1145-1148.
Rodeheffer R. Measuring plasma B-type natriuretic peptide in heart failure Good to go in 2004? J Am Coll Cardiol. 2004;44:740-749.
Cleland JG, Taylor J, Freemantle N, Goode KM, Rigby AS, Tendera M. Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. Eur J Heart Fail. 2012;14:487-494.
Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ. 2005;330:625.
Passantino A, Guida P, Lagioia R, et al. Predictors of long-term mortality in older patients hospitalized for acutely decompensated heart failure: clinical relevance of natriuretic peptides. J Am Geriatr Soc. 2016;65:822-826.
Kitada S, Kikuchi S, Tsujino T, Masuyama T, Ohte N, J-MELODIC study Investigators. The prognostic value of brain natriuretic peptide in patients with heart failure and left ventricular ejection fraction higher than 60%: a sub-analysis of the J-MELODIC study. ESC Heart Fail. 2018;5:36-45.
Welsh P, Kou L, Yu C, et al. Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. Eur J Heart Fail. 2018;20:268-277.
Düngen HD, Tscholl V, Obradovic D, et al. Prognostic performance of serial in-hospital measurements of copeptin and multiple novel biomarkers among patients with worsening heart failure: results from the MOLITOR study. ESC Heart Fail. 2018;5:288-296.
Zhang J, Pellicori P, Pan D, Dierckx R, Clark AL, Cleland JGF. Dynamic risk stratification using serial measurements of plasma concentrations of natriuretic peptides in patients with heart failure. Int J Cardiol. 2018;269:196-200.
Grodin JL, Liebo MJ, Butler J, et al. Prognostic implications of changes in amino-terminal Pro-B-type natriuretic peptide in acute decompensated heart failure: insights from ASCEND-HF. J Card Fail. 2019;25:703-711.
Savarese G, Donal E, Hage C, et al. Changes in natriuretic peptides after acute hospital presentation for heart failure with preserved ejection fraction: A feasible surrogate trial endpoint? A report from the prospective Karen study. Int J Cardiol. 2017;226:65-70.
Sudharshan S, Novak E, Hock K, Scott MG, Geltman EM. Use of biomarkers to predict readmission for congestive heart failure. Am J Cardiol. 2017;119:445-451.
Nielsen OW, McDonagh TA, Robb SD, Dargie HJ. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol. 2003;41:113-120.
Minami Y, Kajimoto K, Sato N, Hagiwara N, Takano T, Mebazaa A. Heterogeneity of the prognostic significance of B-type natriuretic peptide levels on admission in patients hospitalized for acute heart failure syndromes. Eur J Intern Med. 2016;31:41-49.
Namdari M, Eatemadi A, Negahdari B. Natriuretic peptides and their therapeutic potential in heart failure treatment: an updated review. Cell Mol Biol. 2016;62:1-7.
De Wardener HE, Mills IH, Clapham WF, Hayter CJ. Studies on the efferent mechanism of the sodium diuresis which follows the administration of intravenous saline in the dog. Clin Sci. 1961;21:249-258.
McQuade CN, Mizus M, Wald JW, Goldberg L, Jessup M, Umscheid CA. Brain-type natriuretic peptide and amino-terminal pro-brain-type natriuretic peptide discharge thresholds for acute decompensated heart failure. Ann Intern Med. 2016;166:180-190.
Felker GM, Anstrom KJ, Adams KF, et al. Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction. JAMA. 2017;318:713-720.
Stienen S, Salah K, Moons AH, et al. NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-guided therapy in acute decompensated heart failure: PRIMA II randomized controlled trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?). Circulation. 2018;137:1671-1683.
Khan MS, Siddiqi TJ, Usman MS, et al. Does natriuretic peptide monitoring improve outcomes in heart failure patients? A systematic review and meta-analysis. Int J Cardiol. 2018;263:80-87.
Pufulete M, Maishman R, Dabner L, et al. Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model. Health Technol Assess. 2017;21:1-150.
Brunner-La Rocca HP, Eurlings L, Richards AM, et al. Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials. Eur J Heart Fail. 2015;17:1252-1261.
Jarolim P, White WB, Cannon CP, Gao Q, Morrow DA. Serial measurement of natriuretic peptides and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE Trial. Diabetes Care. 2018;41:1510-1515.
Wolsk E, Claggett B, Diaz R, et al. Increases in natriuretic peptides precede heart failure hospitalization in patients with a recent coronary event and type 2 diabetes mellitus. Circulation. 2017;136:1560-1562.
McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004.
Myhre PL, Vaduganathan M, Claggett B, et al. B-type natriuretic peptide during treatment with sacubitril/valsartan: the PARADIGM-HF trial. J Am Coll Cardiol. 2019;73:1264-1272.
Ibrahim NE, McCarthy CP, Shrestha S, et al. Effect of neprilysin inhibition on various natriuretic peptide assays. J Am Coll Cardiol. 2019;73:1273-1284.
Pufulete M, Maishman R, Dabner L, et al. B-type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual participant data (IPD) and aggregate data. Syst Rev. 2018;7:112.
Mohiuddin S, Reeves B, Pufulete M, et al. Model-based cost-effectiveness analysis of B-type natriuretic peptide-guided care in patients with heart failure. BMJ Open. 2016;6:e014010.
Clerico A, Passino C, Franzini M, Emdin M. Natriuretic peptides as biomarkers of cardiac endocrine function in heart failure: new challenges and perspectives. Future Cardiol. 2016;12:573-584.
Clerico A, Franzini M, Masotti S, Prontera C, Passino C. State of the art of immunoassay methods for B-type natriuretic peptides: an update. Crit Rev Clin Lab Sci. 2015;52:56-69.
Prontera C, Zaninotto M, Giovannini S, et al. Proficiency testing project for brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP (NT-proBNP) immunoassays: the CardioOrmocheck study. Clin Chem Lab Med. 2009;47:762-768.
Clerico A, Passino C, Franzini M, Emdin M. Cardiac biomarker testing in the clinical laboratory: where do we stand? General overview of the methodology with special emphasis on natriuretic peptides. Clin Chim Acta. 2015;443:17-24.
Troughton RW, Frampton CM, Yandle TG, Espine EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126-1130.
Hammerer-Lercher A, Neubauer E, Müller S, Pachinger O, Puschendorf B, Mair J. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta. 2001;310:193-197.
Moghtadaei M, Polina I, Rose RA. Electrophysiological effects of natriuretic peptides in the heart are mediated by multiple receptor subtypes. Prog Biophys Mol Biol. 2016;120:37-49.
Egom EE, Maher V, El Hiani Y. Evolving use of natriuretic peptide receptor type-C as part of strategies for the treatment of pulmonary hypertension due to left ventricle heart failure. Int J Cardiol. 2019;281:172-178.
Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev. 2006;27:47-72.
Pandey KN. Guanylyl cyclase/natriuretic peptide receptor-A signaling antagonizes phosphoinositide hydrolysis, Ca2+ release, and activation of protein kinase C. Front Mol Neurosci. 2014;7:75.
Springer J, Azer J, Hua R, et al. The natriuretic peptides BNP and CNP increase heart rate and electrical conduction by stimulating ionic currents in the sinoatrial node and atrial myocardium following activation of guanylyl cyclase-linked natriuretic peptide receptors. J Mol Cell Cardiol. 2012;52:1122-1134.
Azer J, Hua R, Vella K, Rose RA. Natriuretic peptides regulate heart rate and sinoatrial node function by activating multiple natriuretic peptide receptors. J Mol Cell Cardiol. 2012;53:715-724.
Azer J, Hua R, Krishnaswamy PS, Rose RA. Effects of natriuretic peptides on electrical conduction in the sinoatrial node and atrial myocardium of the heart. J Physiol. 2014;592:1025-1045.
Bennett BD, Bennett GL, Vitangcol RV, et al. Extracellular domain-IgG fusion proteins for three human natriuretic peptide receptors. Hormone pharmacology and application to solid phase screening of synthetic peptide antisera. J Biol Chem. 1991;266:23060-23067.
Selektor Y, Weber KT. The salt-Avid state of congestive heart failure revisited. Am J Med Sci. 2008;335:209-218.
Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA. 2005;293:1609-1616.
Goetze JP, Kastrup J, Rehfeld JF. The paradox of increased natriuretic hormones in congestive heart failure patients: does the endocrine heart also fail in heart failure? Eur Heart J. 2003;24:1471-1472.
Gabrielsen A, Bie P, Holstein-Rathlou NH, et al. Neuroendocrine and renal effects of intravascular volume expansion in compensated heart failure. Am J Physiol Regul Integr Comp Physiol. 2001;281:R459-R467.
Boerrigter G, Costello-Boerrigter LC, Harty GJ, Lapp H, Burnett JC. Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am J Physiol Integr Comp Physiol. 2007;292:R897-R901.
Niederkofler EE, Kiernan UA, O’Rear J, et al. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Hear Fail. 2008;1:258-264.
Sarraf M, Masoumi A, Schrier RW. Cardiorenal syndrome in acute decompensated heart failure. Clin J Am Soc Nephrol. 2009;4:2013-2026.
Hotchkiss A, Feridooni T, Baguma-Nibasheka M, McNeil K, Chinni S, Pasumarthi KB. Atrial natriuretic peptide inhibits cell cycle activity of embryonic cardiac progenitor cells via its NPRA receptor signaling axis. Am J Physiol Physiol. 2015;308:C557-C569.
Meier S, Andressen KW, Aronsen JM, et al. PDE3 inhibition by C-type natriuretic peptide-induced cGMP enhances cAMP-mediated signaling in both non-failing and failing hearts. Eur J Pharmacol. 2017;812:174-183.
Moltzau LR, Meier S, Aronsen JM, et al. Differential regulation of C-type natriuretic peptide-induced cGMP and functional responses by PDE2 and PDE3 in failing myocardium. Naunyn Schmiedebergs Arch Pharmacol. 2014;387:407-417.
Dickey DM, Flora DR, Bryan PM, Xu X, Chen Y, Potter LR. Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (NPR)-B, Not NPR-A, is the predominant natriuretic peptide receptor in the failing heart. Endocrinology. 2007;148:3518-3522.
Matsumoto T, Wada A, Tsutamoto T, et al. Vasorelaxing effects of atrial and brain natriuretic peptides on coronary circulation in heart failure. Am J Physiol Circ Physiol. 1999;276:H1935-H1942.
Tsutamoto T, Kanamori T, Morigami N, Sugimoto Y, Yamaoka O, Kinoshita M. Possibility of downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure. Circulation. 1993;87:70-75.
Singh G, Kuc RE, Maguire JJ, Fidock M, Davenport AP. Novel snake venom ligand dendroaspis natriuretic peptide is selective for natriuretic peptide receptor-A in human heart. Circ Res. 2006;99:183-190.
Potter LR. Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases. Pharmacol Ther. 2011;130:71-82.
Haneda M, Kikkawa R, Maeda S, et al. Dual mechanism of angiotensin II inhibits ANP-induced mesangial cGMP accumulation. Kidney Int. 1991;40:188-194.
Jaiswal RK. Endothelin inhibits the atrial natriuretic factor stimulated cGMP production by activating the protein kinase C in rat aortic smooth muscle cells. Biochem Biophys Res Commun. 1992;182:395-402.
Li D, Lu CJ, Hao G, et al. Efficacy of B-type natriuretic peptide is coupled to phosphodiesterase 2A in cardiac sympathetic neurons. Hypertension. 2015;66:190-198.
Nakagawa Y, Nishikimi T, Kuwahara K, et al. Axis-mediated glycosylation contributes to the increased secretion of inactive human prohormone for brain natriuretic peptide (proBNP) From Failing Hearts. J Am Heart Assoc. 2017;6(2):e003601.
Takahama H, Takashio S, Nishikimi T, et al. Ratio of pro-B-type natriuretic peptide (BNP) to total BNP is decreased in mild, but not severe, acute decompensated heart failure patients: A novel compensatory mechanism for acute heart failure. Int J Cardiol. 2018;258:165-171.
Volpe M, Tritto C, De Luca N, et al. Failure of atrial natriuretic factor to increase with saline load in patients with dilated cardiomyopathy and mild heart failure. J Clin Invest. 1991;88:1481-1489.
Charloux A, Piquard F, Doutreleau S, Brandenberger G, Geny B. Mechanisms of renal hyporesponsiveness to ANP in heart failure. Eur J Clin Invest. 2003;33:769-778.
Goetze JP. Biochemistry of pro-B-type natriuretic peptide-derived peptides: The endocrine heart revisited. Clin Chem. 2004;50:1503-1510.
Dong N, Chen S, Yang J, et al. Plasma soluble corin in patients with heart failure. Circ Hear Fail. 2010;3:207-211.
Supaporn T, Sandberg SM, Borgeson DD, et al. Blunted cGMP response to agonists and enhanced glomerular cyclic 3’,5’-nucleotide phosphodiesterase activities in experimental congestive heart failure. Kidney Int. 1996;50:1718-1725.
Wilkins MR, Settle SL, Needleman P. Augmentation of the natriuretic activity of exogenous and endogenous atriopeptin in rats by inhibition of guanosine 3’,5’-cyclic monophosphate degradation. J Clin Invest. 1990;85:1274-1279.
Kaye DM, Lambert GW, Lefkovits J, Morris M, Jennings G, Esler MD. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol. 1994;23:570-578.
Aggarwal A, Esler MD, Socratous F, Kaye DM. Evidence for functional presynaptic alpha-2 adrenoceptors and their down-regulation in human heart failure. J Am Coll Cardiol. 2001;37:1246-1251.
Böhm M, Maack C. Treatment of heart failure with beta-blockers. Mechanisms and results. Basic Res Cardiol. 2000;95:I15-I24.
SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
Clark AL, Cleland JG. The control of adrenergic function in heart failure: therapeutic intervention. Heart Fail Rev. 2000;5:101-114.
Kuhn M, Voss M, Mitko D, et al. Left ventricular assist device support reverses altered cardiac expression and function of natriuretic peptides and receptors in end-stage heart failure. Cardiovasc Res. 2004;64:308-314.
Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293:1900-1905.
Gong B, Wu Z, Li Z. Efficacy and safety of nesiritide in patients with decompensated heart failure: a meta-analysis of randomised trials. BMJ Open. 2016;6:e008545.
Chen HH, Glockner JF, Schirger JA, Cataliotti A, Redfield MM, Burnett JC. Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. J Am Coll Cardiol. 2012;60:2305-2312.
Yancy CW, Krum H, Massie BM, et al. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure. Circ Hear Fail. 2008;1:9-16.
Hata N, Seino Y, Tsutamoto T, et al. Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure. Circ J. 2008;72:1787-1793.
Cody RJ, Atlas SA, Laragh JH, et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest. 1986;78:1362-1374.
Saito Y, Nakao K, Nishimura K, et al. Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function. Circulation. 1987;76:115-124.
Wang G, Wang P, Li Y, et al. Efficacy and safety of 1-hour infusion of recombinant human atrial natriuretic peptide in patients with acute decompensated heart failure. Medicine (Baltimore). 2016;95:e2947.
Bryan PM, Xu X, Dickey DM, Chen Y, Potter LR. Renal hyporesponsiveness to atrial natriuretic peptide in congestive heart failure results from reduced atrial natriuretic peptide receptor concentrations. Am J Physiol Physiol. 2007;292:F1636-F1644.
Mitrovic V, Forssmann WG, Schnitker J, Felix SB. Randomized double-blind clinical studies of ularitide and other vasoactive substances in acute decompensated heart failure: a systematic review and meta-analysis. ESC Hear Fail. 2018;5:1023-1034.
Lisy O, Huntley BK, McCormick DJ, Kurlansky PA, Burnett JC. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol. 2008;52:60-68.
Langenickel TH, Buttgereit J, Pagel-Langenickel I, et al. Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B. Proc Natl Acad Sci. 2006;103:4735-4740.
Wang Y, de Waard MC, Sterner-Kock A, et al. Cardiomyocyte-restricted over-expression of C-type natriuretic peptide prevents cardiac hypertrophy induced by myocardial infarction in mice. Eur J Heart Fail. 2007;9:548-557.
Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the β-adrenergic pathway. Circulation. 1998;98:1329-1334.
Vatner DE, Asai K, Iwase M, et al. Beta-adrenergic receptor- G protein-adenylyl cyclase signal transduction in the failing heart. Am J Cardiol. 1999;83:80-85.
Hobbs A, Foster P, Prescott C, Scotland R, Ahluwalia A. Natriuretic peptide receptor-c regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury. Circulation. 2004;110:1231-1235.
Hayoz D, Drexler H, Munzel T, et al. Flow-mediated arterial dilation is abnormal in congestive heart failure. Circulation. 1993;87:e570.